60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome

60 Degrees is funding early-stage research on castanospermine for tick-induced allergies.

What the company is saying

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) is expanding its vector-borne disease research portfolio by entering a sponsored research agreement with The University of Southern Mississippi (USM). The company is underwriting nonclinical studies to assess castanospermine, a compound from the Australian Chestnut, as a potential therapy for alpha-gal syndrome (AGS), a severe tick-induced allergy. The company emphasizes the lack of FDA-approved treatments for AGS and frames this as an unmet need. 60 Degrees retains an option to commercialize any resulting intellectual property and is considering a botanical regulatory pathway before a full prescription drug program. The announcement highlights USM’s expertise in vector biology and tick-borne disease but does not quantify expected outcomes. The tone is measured, focusing on research-stage progress rather than near-term commercial impact. The company also references its 2018 FDA approval for ARAKODA® (tafenoquine) for malaria prevention and notes three active clinical trials for babesiosis.

What the data suggests

The only concrete operational step disclosed is the execution of a sponsored research agreement with USM, with 60 Degrees underwriting the research costs. The company holds an option to commercialize any resulting intellectual property, but no financial terms, research budgets, or timelines are provided. The company has a track record of regulatory success, having received FDA approval for ARAKODA® in 2018, and is running three clinical trials for babesiosis. The announcement confirms that AGS currently lacks FDA-approved treatments, underscoring the potential market opportunity if the research is successful. There are no claims of efficacy, clinical results, or regulatory submissions for castanospermine at this stage. The disclosure is specific about the research stage and the intended regulatory exploration but offers no evidence of technical or commercial progress beyond the agreement itself.

Analysis

The announcement is proportionate in tone, focusing on the execution of a sponsored research agreement with The University of Southern Mississippi to investigate castanospermine for alpha-gal syndrome. The majority of claims are realised and factual: the agreement is signed, the research will be underwritten, and the company retains an option to commercialize any resulting IP. Only two key claims are forward-looking: the intention to explore regulatory pathways and the expectation that nonclinical research will inform future decisions. There is no exaggeration of imminent commercial or financial impact, and no large capital outlay or near-term earnings impact is implied. The language is measured, with no inflated projections or unsupported claims of efficacy or market potential. The absence of financial or profitability data is not a deficiency here, as this is a research-stage collaboration announcement.

Risk flags

• ●The research is at a very early, nonclinical stage, so there is a high risk that castanospermine will not demonstrate efficacy or safety in models of alpha-gal syndrome. Failure at this stage would halt further development.
• ●No financial terms or research budget are disclosed, making it impossible to assess the capital at risk or the financial impact on 60 Degrees. This lack of transparency limits visibility into the company's resource allocation and runway.
• ●There is no guarantee that a botanical approval pathway will be viable or that the FDA will accept such an approach for AGS, introducing regulatory risk and uncertainty about the eventual commercialization route.
• ●The company is reliant on external academic expertise (USM) for this research, which may introduce execution risk if priorities or resources shift at the partner institution.

Bottom line

This announcement signals 60 Degrees Pharmaceuticals’ intent to build a pipeline beyond malaria by funding preclinical research into castanospermine for alpha-gal syndrome, an area with no approved therapies. The deal is limited to underwriting research at USM and retaining commercial rights, with no disclosed financial terms, timelines, or technical milestones. Investors should see this as a long-term, high-risk research-stage effort with no near-term revenue or commercial catalysts. The company’s prior FDA approval for ARAKODA® and ongoing babesiosis trials show it can advance products to later stages, but there is no evidence yet that castanospermine will progress beyond nonclinical work. The most important takeaway is that this is a pipeline option, not a value driver, until further research results or regulatory progress are disclosed.

Announcement summary

(NASDAQ:SXTP) 60 Degrees Pharmaceuticals, Inc. announced the expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM). The agreement will assess the therapeutic potential of castanospermine, a naturally occurring iminosugar derived from the Australian Chestnut (Castanospermum australe), in nonclinical models of alpha-gal syndrome (AGS). The partnership leverages USM’s expertise in vector biology research and tick-borne disease. Under the agreement, 60 Degrees Pharmaceuticals will underwrite the research and retains an option to commercialize and market any resulting intellectual property. The company plans to explore potential botanical approval pathways for a castanospermine-containing product before starting a prescription drug development program. The nonclinical research at USM is expected to inform this assessment and guide subsequent development decisions. AGS is an increasingly recognized tick-associated allergic condition, most commonly linked in the United States to bites from the lone star tick. AGS can cause severe and potentially life-threatening allergic reactions following ingestion of, or exposure to, products containing galactose-α-1,3-galactose (alpha-gal), a carbohydrate found in most non-primate mammalian meat and other mammalian-derived products, including beef, pork, lamb, and certain dairy products. Humans do not produce alpha-gal and may develop antibodies against it following tick exposure. There are currently no FDA-approved medications specifically indicated to treat or prevent AGS, and current management relies primarily on avoidance of foods and other products that trigger allergic reactions. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The company obtained U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. The company currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. 60 Degrees also collaborates with prominent research and academic organizations in the United States and Australia to advance science around vector-borne disease. The company is headquartered in Washington, D.C., with a subsidiary in Australia.

Disagree with this article?